IONS Dec 2023 55.000 call
| Previous Close | 0.9000 |
| Open | 0.9000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 55.00 |
| Expire Date | 2023-12-15 |
| Day's Range | 0.9000 - 0.9000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksIonis Pharmaceuticals (IONS) Up 19.3% Since Last Earnings Report: Can It Continue?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksIonis (IONS) Q1 Earnings Surpass Estimates, Sales Match
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
- Thomson Reuters StreetEvents
Q1 2023 Ionis Pharmaceuticals Inc Earnings Call
Q1 2023 Ionis Pharmaceuticals Inc Earnings Call
ZacksHere's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q1 Earnings
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksIonis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 13% and 0.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksAvalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolCould This Rare-Disease Drug Candidate Become a Blockbuster?
This drug candidate could be a great treatment option for patients with a potentially deadly disease.
ZacksIonis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
ZacksWhy Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
ZacksIonis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to Decline
Relay Therapeutics, Inc. (RLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Institutional investors in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) lost 4.6% last week but have reaped the benefits of longer-term growth
Every investor in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) should be aware of the most powerful shareholder groups...
ZacksAvita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?
Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have endured a 41% loss from investing in the stock three years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
GlobeNewswireRoyalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of royalties and all milestones from Novartis for pelacarsenRoyalty Pharma to pay Ionis $500 million upfront and up to $625 million in milestonesAgreement enables Ionis to achieve commercial readiness for multiple late-stage programs and advance its innovative pipeline of genetic medicines NEW YORK and CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ionis
GlobeNewswireBiogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Alcyone’s ThecaFlex DRx™ System is an implantable medical device in development for intrathecal drug delivery CAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space. Through this agreeme
ZacksWhy Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksBiogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
ZacksIonis (IONS) Inks Deal to Develop Precision Genetic Medicines
Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.
- Simply Wall St.
Should You Be Worried About Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 1.2% Return On Equity?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
ZacksIonis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.
ZacksIonis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?